trial · primary record
Olaparib (300 mg BID)
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
| Phase | Phase 1 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | Not stated |
| Primary completion | 2028-12-01 |
| Primary endpoint | Progression Free Survival |
| Registry ID | NCT07090369 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:12.637Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07090369
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.